Yes, GSTs can serve as potential biomarkers for cancer prognosis and treatment response. For instance, elevated levels of GSTP1 can indicate poor prognosis and resistance to chemotherapy in certain cancers like prostate cancer and breast cancer. Additionally, GST polymorphisms can serve as genetic markers for cancer susceptibility.
